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Abstract
Over the last five years, the number of clinical trials involving AAV (adeno-associated virus) and 
lentiviral vectors continue to increase by about 150 trials each year. For continued success, AAV 
and lentiviral expression cassettes need to be designed to meet each disease's specific needs. This 
review discusses how viral vector expression cassettes can be engineered with elements to 
enhance target specificity and increase transgene expression. The key differences relating to target 
specificity between ubiquitous and tissue-specific promoters are discussed, as well as how 
endogenous miRNAs and their target sequences have been used to restrict transgene expression. 
Specifically, relevant studies indicating how cis-acting elements such as introns, WPRE, 
polyadenylation signals, and the CMV enhancer are highlighted to show their utility for enhancing 
transgene expression in gene therapy applications. All discussion bears in mind that expression 
cassettes have space constraints. In conclusion, this review can serve as a menu of vector genome 
design elements and their cost in terms of space to thoughtfully engineer viral vectors for gene 
therapy.
Introduction
The cis-acting elements that regulate transgene expression can have as great of an impact on 
the success of gene therapy as the design of the vector capsid or envelope. Target specificity 
and an appropriate level of transgene expression can prevent unwanted phenotypes in other 
cells, an immune response, and possible toxicity. Overexpression and non-targeted 
expression in some diseases, such as Rett Syndrome, is to be avoided (Amir et al., 1999); 
however, in Hemophilia B, expression of Factor IX, a secreted protein present in the blood, 
is needed to be high and there is little concern of overexpression (reviewed in Cancio et al., 
2013).
Lentivirus and AAV (adeno-associated virus) expression cassettes, prominently used in gene 
therapy, can be designed for target specificity and transgene expression levels (Figure 1). 
Target specificity can be honed by using cell-specific promoters or endogenous miRNAs. 
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Transgene expression levels can be modulated by engineering the expression cassette to 
include the CMV enhancer (that includes transcription factor binding sites) or mRNA 
stability/nuclear export cis-acting elements (introns, polyA signals, or WPRE). Expression 
cassettes require thoughtful design due to foreign DNA packaging size constraints of AAV 
and lentivirus, approximately 4.1–4.9 kbs and 8–9 kbs, respectively (Dong et al., 1996; 
Kumar et al., 2001). While keeping in mind size constraints, this review will discuss 
different cis-acting elements that have been engineered into lentivirus and AAV expression 
cassettes to enhance cell-specific transgene expression. Lentivirus and AAV have been 
extensively reviewed elsewhere in the areas of their pros and cons, virology, uses, and 
development for gene transfer (Nagabhushan Kalburgi et al., 2013; Kay et al., 2011; Grieger 
and Samulski, 2012; Segura et al., 2013). Other outstanding reviews are available for 
insulators (Antoniou et al., 2013), self-complementary AAV (McCarty, 2008), AAV 
serotype tropism (Wu et al., 2006), retrovirus pseudotyping (Matrai et al., 2010), and 
systems to induce/regulate expression using exogenously supplied trans-acting factors 
(Toniatti et al., 2004). Although these are useful tools to control expression and/or cell 
specificity, they will not be discussed in this review. Moreover, while the genome 
modifications are described in this review in the context of AAV and lentiviral vectors, they 
are certainly applicable to other vector systems.
Promoters
An effective gene transfer approach must be directed to the specific tissues/cells where it is 
needed, and the resulting transgene expression should be at a level that is appropriate to the 
specific application. Promoters are a major cis-acting element within the vector genome 
design that can dictate the overall strength of expression as well as cell-specificity (Table 1).
Ubiquitous expression
In some cases, such as those where a gene product is secreted, ubiquitous expression in all 
cell types is desired. Constitutive promoters such as the human elongation factor 1α-subunit 
(EF1α), immediate-early cytomegalovirus (CMV), chicken β-actin (CBA) and its derivative 
CAG, the β glucuronidase (GUSB), or ubiquitin C (UBC) can be used to promote expression 
in most tissues (Husain et al., 2009; Qin et al., 2010; Norrman et al., 2010). Generally, CBA 
and CAG promote the larger expression among the constitutive promoters (Xu et al., 2001; 
Yin et al., 2011); however, their size of ~1.7 kbs in comparison to CMV (~0.8 kbs) or EF1α 
(~1.2 kbs) limits its use in vectors with packaging constraints such as AAV. The GUSB or 
UBC promoters can provide ubiquitous gene expression with a smaller size of 378 bps and 
403 bps, respectively, but they are considerably weaker than the CMV or CBA promoter 
(Husain et al., 2009; Qin et al., 2010). Thus, modifications to constitutive promoters in order 
to reduce the size without affecting its expression have been pursued and examples such as 
the CBh (~800 bps) and the miniCBA (~800 bps) can promote expression comparable and 
even higher in selected tissues (Gray et al., 2011). It should be noted that in some cases 
“ubiquitous” promoters can be prone to silencing or promote differential expression strength 
in selected cell types (McCown et al., 1996; Klein et al., 1998; Gray et al., 2011).
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When expression should be restricted to certain cell types within an organ, promoters can be 
used to mediate this specificity. For example, within the nervous system promoters have 
been used to restrict expression to neurons, astrocytes, or oligodendrocytes. In neurons, the 
neuron-specific enolase (NSE) promoter drives stronger expression than ubiquitous 
promoters (Xu et al., 2001); however, its size of 2.2 kbs limits its use in smaller vectors. 
Additionally, the platelet-derived growth factor B-chain (PDGF-β), the synapsin (Syn), and 
the methyl-CpG binding protein 2 (MeCP2) promoters can drive neuron-specific expression 
at lower levels than NSE, but their sizes of 1.4 kbs, 470 bps and 229 bps, respectively, make 
them more suitable for vectors with limitations in size (Paterna et al., 2000; Kügler et al., 
2003; Hioki et al., 2007; Kuroda et al., 2008; Rastegar et al., 2009; Gray et al., 2011). In 
astrocytes, the 680 bps-long shortened version [gfaABC(1)D] of the glial fibrillary acidic 
protein (GFAP, 2.2 kbs) promoter can confer higher levels of expression with the same 
astrocyte-specificity as the GFAP promoter (Lee et al., 2008). Targeting oligodendrocytes 
can also be accomplished by the selection of the myelin basic protein (MBP) promoter, 
whose expression is restricted to this glial cell; however, its size of 1.9 kbs and low 
expression levels limit its use (Chen et al., 1998).
Following systemic administration of vectors, cell- or tissue-specific promoters can be used 
to restrict expression away from the liver. In skeletal muscle cells, the promoters based on 
muscle creatine kinase (MCK) and desmin (1.7 kbs) have showed a high rate of specificity 
with minimal invasion to the liver (Wang et al., 2008; Talbot et al., 2010; Katwal et al., 
2013). The promoter of the α-myosin heavy chain (α-MHC; 1.2 kbs) has shown significant 
cardiac specificity in comparison with other muscle promoters (Lee et al., 2011). In 
hematopoietic stem cells the synthetic MND promoter (Li et al., 2010) and the promoter 
contained in the 2AUCOE (ubiquitous chromatin opening element) have shown to drive a 
higher transgene expression in all cell lineages when compared to the EF1α and CMV 
promoters, respectively (Zhang et al., 2007; Koldej 2013; Dighe et al., 2014). Conversely, 
using promoters to restrict expression to only liver hepatocytes after vector-mediated gene 
transfer has been shown to avoid transgene-specific immune responses, and to even induce 
immune tolerance to the expressed protein (Zhang et al., 2012). The α1-antitrypsin (hAAT; 
347 bps) and the thyroxine binding globulin (TBG; ~400 bps) promoters drive gene 
expression restricted to the liver with minimal invasion to other tissues (Yan et al., 2012; 
Cunningham et al., 2008).
Tissue specific promoters provide the advantage of limiting the expression to the desired cell 
or tissue. However, low levels of expression and/or large size may limit their use. To 
compensate for weak strength, the level of expression can be increased by adding enhancer 
elements such as from CMV (see below). Conversely, as mentioned above, these promoters 
can be modified in order to reduce their capabilities and overall strength.
Endogenous MicroRNAs
MicroRNAs (miRNAs) are 21–23 oligonucleotide RNA molecules that control protein 
expression by repressing genes post-transcriptionally in a tissue-, cell-, developmental-, or 
metabolic-specific manner (reviewed in Broderick and Zamore, 2011). Endogenous 
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miRNAs can `de-target' or inhibit transgene expression when their exact complementary 
target sequences are engineered into an expression cassette. The level of repression, in vitro, 
correlates with the number of target sequences within the expression cassette (Doench et al., 
2003; Brown et al., 2006; 2007). As an example, 4 copies of the hematopoietic-specific 
miR-142-3p target sequence (miR-142-3pT) were engineered into a lentivirus vector with a 
reporter transgene being driven by the ubiquitous PGK (phosphoglycerate kinase) promoter 
(Brown et al., 2006). In fact, miR-142-3p was still able to maintain expression inhibition 
even if cells were overloaded with up to 30 viral genomes per cell (Brown et al., 2006). The 
miR-142-3pT containing viruses, when injected intravenously into mice, inhibited transgene 
expression in Kupffer cells and restricted transgene expression to hepatocytes and liver 
endothelial cells (Brown et al., 2006). Transgene expression was further restricted to only 
liver endothelial cells, when 4 copies of miR-142-3pT and 4 copies of miR-122aT were 
combined within an expression cassette (Brown et al., 2007). In another in vivo study, when 
an engineered lentiviral vector containing 4 copies of the neuronal-specific miR-124 target 
sequence was injected into mouse brain, PGK-driven transgene expression was de-targeted 
from neurons to only astrocytes (Colin et al., 2009). Endogenous miRNAs are a useful tool 
in obtaining transgene cell specificity because their respective binding sites are small, can be 
combined, and are robust in their ability to restrict expression.
Post-transcriptional Regulatory Elements
Viral post-transcriptional regulatory elements (PREs) are important for viral gene 
expression; these cis-acting elements are required for nuclear export of intronless viral RNA 
(Huang and Yen, 1994; 1995). Both HPRE (Hepatitis B Virus PRE, 533 bps) and WPRE 
(Woodchuck Hepatitis Virus PRE, 600 bps) were assessed, in vitro, and the level of 
transgene expression was increased 6.1-fold and 8.6-fold, respectively (Donello et al., 
1998). The difference in expression was determined to be due to an additional sequence 
element in WPRE (Donello et al., 1998). WPRE can be shortened (to 247 bps), as 
demonstrated in neurons in vivo and in vitro, and it still offers sufficient transgene 
expression (Choi et al., 2014). In cultured human cells using lentiviral and AAV vectors, 
WPRE was found to increase CMV promoter driven transgene expression up to 8-fold (Loeb 
et al., 1999; Zufferey et al., 1999). In vivo studies have also shown an increase of PPE, 
PDGF, NSE, or CMV promoter-driven transgene expression by the presence of WPRE 
(Paterna et al., 2000; Xu et al., 2001). Importantly, transgene expression was not 
significantly increased by including WPRE, in vitro and in vivo, when driven from either the 
EFα1 or CAG promoter due to an intron in the promoters (Ramezani et al., 2000; Fagoe et 
al., 2014). Another effect of the WPRE is to protect transgenes from silencing, as seen when 
it was combined with the CMV or CAG promoter in human ES cells and in the brain 
(Paterna et al., 2000; Xia et al., 2007). In conclusion, although the WPRE can boost 
expression and prevent long-term silencing in combination with several promoters, the 
presence of an intron seems to mitigate its effectiveness in boosting transgene expression 
levels.
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Polyadenylation Signal Sequences and Upstream Enhancer
The polyadenylation of a transcript is critical for nuclear export, translation, and mRNA 
stability. Therefore, the efficiency of transcript polyadenylation is important for transgene 
expression. In vitro studies using mammalian cultured cells have been useful in determining 
the effects of different polyA signals to boost expression. One study, in human epithelial-
like cells, found that a transgene had a 2.5-fold increase in expression with either SV40 late 
or bovine growth hormone polyA (bGHpA) signal sequences compared to a minimal 
synthetic polyA (SPA) signal (Levitt et al., 1989; Yew et al., 1997). Some of the same 
polyA signals were assessed in neuronal cell cultures and gave similar results; the late SV40 
polyA signal and bGHpA were approximately equivalent and twice as strong as the minimal 
SPA (Choi et al., 2014). In vivo, the bGHpA signal, when packaged into AAV2 and injected 
intravenously into mice, gave 2- to 3-fold more transgene expression over the mouse β-
globin polyA signal (Wu et al., 2008). Together these results suggest that polyA signal 
strength is independent of cell type and that in vitro results generally correlate with in vivo 
observations.
The efficiency of polyadenylation is increased by the SV40 late polyA signal upstream 
enhancer (USE) placed upstream of other polyA signals (Schek et al., 1992). The SV40 late 
+ 2xUSE polyA signal compared to SV40 late polyA signal alone gave about a 2-fold 
increase in transgene expression (Schambach et al., 2007; Choi et al., 2014). SV40 late 
+2xUSE polyA signal also increased transgene expression by 45–100% when compared to a 
variety of other USEs (Schambach et al., 2007). In vivo, bGHpA and SV40 late +2xUSE 
polyA signals, when injected into mouse hippocampus, gave similar levels of increased 
transgene expression compared to the control (Choi et al., 2014). Interestingly, a study 
comparing SV40 late +2xUSE polyA signal and a shortened WPRE (247 bps) to bGHpA 
and WPRE found that both increased transgene expression to a similar level; however, the 
first construct is about 400 bps shorter (Schambach et al., 2007). These results are 
summarized in Table 2.
CMV Enhancer
The CMV enhancer is upstream of the CMV promoter at −598 to −68 (Boshart et al., 1985) 
(~600 bps) and contains transcription binding sites. In cultured cells, the presence of the 
CMV enhancer increased tissue-specific promoter-driven transgene expression 4-, 8-, 45-, 
and 90-fold in cardiomyocytes using the ANF (atrial natriuretic factor) promoter, in mouse 
and human epithelial cells using the CC10 (club cell 10) promoter, in lung epithelial cells 
using the SP-C (surfactant protein C) promoter, and in neurons using the PDGF-β (platelet-
derived growth factor-β) promoter, respectively (Yew et al., 1997; Liu, B. et al., 2004; Gruh 
et al., 2008). Strikingly, in neuronal cell culture, the CMV enhancer and tissue-specific 
promoter drove transgene expression levels as strong as the CMV enhancer and promoter 
(Liu et al., 2004). In vivo mouse studies, using a modified AAV2 intravenously injected into 
mice, found that using the CMV enhancer upstream of a cardiac muscle promoter resulted in 
50-fold more transgene expression in the heart than with the CMV promoter alone (Muller 
et al., 2006). Also in AAV, in vivo when injected directly into muscle, transgene expression 
using the CMV enhancer with a synthetic muscle-specific promoter (C5-12) was similar to 
Powell et al. Page 5













the CMV promoter level and 50% more than the C5-12 promoter alone (Liu et al., 2004). 
Together, the CMV enhancer increases transgene expression under different cell-specific 
promoters and different cell types making it a broadly applicable tool to increase transgene 
expression levels.
Introns
The presence of an intron or intervening sequence in mRNA was first described, in vitro, to 
be important for mRNA processing and increased transgene expression (Huang and 
Gorman, 1990; Niwa et al., 1990). Early in vitro comparison studies indicated that the SV40 
intron did not increase transgene expression in mouse lung epithelial cells when placed 
between the promoter and transgene, while a hybrid intron (adenovirus/mouse 
immunoglobulin) increased transgene expression by 1.6-fold (Yew et al., 1997). However, 
the presence of the SV40 intron between the promoter and the transgene, in an AAV 
expression cassette, gave a 2-fold increase of transgene expression under the CMV promoter 
and enhancer in lung carcinoma cells (Ostedgaard et al., 2005). A variety of introns (Table 
3) placed between the promoter and transgene were compared, in mice using AAV2, for 
liver transgene expression (Wu et al., 2008). The MVM (minute virus of mice) intron 
increased transgene expression more than any other intron tested and more than 80-fold over 
no intron (Wu et al., 2008). However, in cultured neurons using AAV expression cassettes, 
transgene expression was less under a CaMPKII promoter with a chimeric intron (human β-
globin donor and immunoglobulin heavy chain acceptor) between the transgene and polyA 
signal compared to a WPRE (Choi et al., 2014). Together, an intron can be a valuable 
element to include in an expression cassette to increase transgene expression.
Summary
AAV and lentiviral expression cassettes for gene therapy can be engineered to enhance 
transgene target specificity and expression. The specificity of transgene expression can be 
controlled using cell-specific promoters and endogenous miRNAs. The overall strength of 
expression can be increased up to 90-fold with the CMV enhancer or up to 80-fold by 
improving mRNA stability/nuclear export with a WPRE, polyA signal, an USE, or an intron. 
The combination of these elements must be given thoughtful consideration in order to 
adhere to the space constraints of AAV and lentivirus vectors for gene therapy.
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Cartoon diagram of a generic AAV or lentiviral expression cassette design indicating where 
modular regulatory elements would be placed. The promoter, ITR (inverted terminal 
repeats)/LTR (long terminal repeats), and polyA are essential. The other elements are 
optional. CE, CMV enhancer; I, intron; W, WPRE; M, miRNA target sequences; U, polyA 
upstream enhancer; pA, polyA signal.
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Table 1
Comparison of Selected Ubiquitous and Cell-specific Promoters.
Promoter Specificity Relative Strength Size (bps) Reference(s)




Ubiquitous +++ 248–1,600 Klein et al., 2002; Ohlfest et al., 2005; Gray et al., 
2011
EF-1α Ubiquitous ++ 2,500 Gill et al., 2001; Xu et al., 2001; Ikeda et al., 
2002; Gilham et al., 2010
PGK Ubiquitous ++ 426 Gilham et al., 2010
UBC Ubiquitous + 403 Gill et al., 2001; Qin et al., 2010
GUSB (hGBp) Ubiquitous + 378 Husain et al., 2009
UCOE (Promoter of 
HNRPA2B1-CBX3)
Ubiquitous ++ 600–2,500 Antoniou et al., 2013
hAAT Liver ++ 347–1,500 Van Linthout et al., 2002; Cunningham et al., 
2008
TBG Liver ++ 400 Yan et al., 2012
Desmin Skeletal muscle +++ 1,700 Talbot et al., 2010
MCK Skeletal muscle ++ 595–1,089 Wang et al., 2008; Talbot et al., 2010; Katwal et 
al., 2013
C5-12 Skeletal, cardiac, and 
diaphragm
++ 312 Wang et al., 2008
NSE Neuron +++ 300–2,200 Xu et al., 2001
Synapsin Neuron + 470 Kügler et al., 2003; Hioki et al., 2007; Kuroda et 
al., 2008
PDGF Neuron +++ 1,400 Patterna et al., 2000; Hioki et al., 2007
MecP2 Neuron + 229 Rastegar et al., 2009; Gray et al., 2011
CaMKII Neuron ++ 364–2,300 Hioki et al., 2007; Kuroda et al., 2008
mGluR2 Neuron + 1,400 Brené et al., 2000; Kuroda et al., 2008
NFL Neuron + 650 Xu et al., 2001
NFH Neuron + 920 Xu et al., 2001
nβ2 Neuron + 650 Xu et al., 2001
PPE Neuron + 2,700 Xu et al., 2001
Enk Neuron + 412 Xu et al., 2001
EAAT2 Neuron and astrocyte ++ 966 Su et al., 2003; Kuroda et al., 2008
GFAP Astrocyte ++ 681–2,200 Brenner et al., 1994; Xu et al., 2001; Lee et al., 
2008; Dirren et al., 2014
MBP Oligodendrocytes ++ 1,900 Chen et al., 1998
Note: Cell type specificity, relative strength (+ being the weakest and +++ being the strongest), size, and relevant references for commonly used 
promoters.
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Table 2
Comparison of PolyA Signals and USEs.
PolyA Signal and USE Relative Strength Size (bps) Source Reference(s)
hGH + 624 Human growth hormone Ostedgaard et al., 2005
SV40 late +++ 135 Simian virus 40 Choi et al., 2014
SPA (synthetic polyA) + 49 Rabbit β-globin Levitt et al., 1989; Yew et al., 1997; 
Ostedgaard et al., 2005; Choi et al., 2014
bGH ++ 250 Bovine growth hormone Yew et al., 1997; Xu et al., 2001; Wu et 
al., 2008; Gray et al., 2011; Choi et al., 
2014
SV40 late 2xUSE ++ 100 Simian virus 40 Schambach et al., 2007; Choi et al., 2014
HIV-1 USE + 35 Human immunodeficiency virus 
1
Schambach et al., 2007
GHV USE + 39 Ground squirrel hepatitis virus Schambach et al., 2007
Adenovirus (L3) USE + 21 Adenovirus Schambach et al., 2007
hTHGB USE + 21 Human prothrombin Schambach et al., 2007
hC2 USE + 53 Human C2 complement gene Schambach et al., 2007
Note: The relative strength (+ being the weakest and +++ being the strongest), source, size, and relevant references for each polyA signal or USE is 
listed.
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Table 3
Comparison of Introns.
Intron Relative Strength Size (bps) Source Reference(s)
MVM +++ 67–97 Minute virus of mice Wu et al., 2008
F.IX truncated intron 1 + 300 Human factor IX Wu et al., 2008; Kurachi et al., 1995
β-globin SD / immunoglobin heavy 
chain SA
+ 250 Human, pZac2.1 Wu et al., 2008; Choi et al., 2014
Adenovirus SD# / immunoglobulin 
SA*
++ 500 pAdβ Wong et al., 1985; Yew et al., 1997
SV40 late SD# / SA* (19S/16S) + 180 pCMVβ Yew et al., 1997
Hybrid adenovirus SD# / IgG SA* +++ 230 Adenovirus Choi et al., 1991; Huang and Gorman, 
1990
Note: The relative strength (+ being the weakest and +++ being the strongest), source, size, and relevant references for each intron is listed. SD#, 
splice donor; SA*, splice acceptor.
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